Semax
Also known as: NA-Semax
Synthetic ACTH Analog | Nootropic & Neuroprotective Peptide
Overview
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4-10, originally developed in Russia for stroke recovery. It achieves enhanced CNS penetration through direct transport via olfactory epithelium and trigeminal nerves, bypassing the blood-brain barrier.
Key benefits
- Rapid brain delivery via intranasal route
- Rapidly increases BDNF levels
- Extensive clinical research in Russia
- Easy self-administration
- Modulates dopamine and serotonin systems
- Neuroprotective effects
Mechanism of action
Rapidly increases BDNF levels, modulates dopaminergic and serotonergic systems, and achieves direct brain delivery through olfactory transport with 0.093% blood-brain barrier penetration (vs 0.01% IV).
Molecular data
- Type
- ACTH(4-10) synthetic analog
- Half-life
- 0.5-2 hours
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cognitive
Neuroprotection
Neuroplasticity
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 300-600mcg | 1-2x daily | — |
| — | 600-900mcg | 2-3x daily | — |
| — | 900-1500mcg | 2-3x daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 500-750mcg | 1x daily | — |
| — | 750-1000mcg | 1-2x daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Mild nasal discomfort (nasal route)
- Possible nasal sensation upon administration
Contraindications
- Pregnancy or breastfeeding
- Known peptide allergies
- Do not exceed 4-week continuous use without medical supervision
Monitoring
- Start with lowest effective dose (300mcg) to assess individual response
- Avoid concurrent intranasal vasoconstrictors
- Monitor for nasal irritation/bleeding
- May enhance stimulant effects - reduce other stimulant doses
References
Primary literature and clinical-trial data informing this entry.